Dose-finding Study Comparing Efficacy and Safety of a PARP Inhibitor Against Doxil in BRCA+ve Advanced Ovarian Cancer

• Status: Completed
• Trial end date: 2018-09-19
• Target enrollment: 0
• Participant gender: Female

Summary

The purpose of the study is to compare the efficacy and safety of 2 doses of drug AZD2281 against liposomal doxorubicin to see which is effective and well tolerated in treating patients with measurable BRCA1- or BRCA2-positive advanced ovarian cancer and who have failed previous platinum therapy.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Treatments: Doxorubicin; Liposomal doxorubicin; Olaparib

Criteria

Inclusion Criteria:

• Advanced ovarian cancer with positive BRCA1 or BRCA2 status

• Progressive or recurrent disease after platinum-based chemotherapy

• Measurable disease by RECIST

Exclusion Criteria:

• Previous anthracycline treatment

• Brain metastases

• Less than 28 days since last treatment used to treat the disease

• Considered a poor medical risk due to a serious uncontrolled disorder